Free Trial

Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

Cyclerion Therapeutics logo
$3.64 +0.09 (+2.54%)
Closing price 07/11/2025 03:50 PM Eastern
Extended Trading
$3.59 -0.05 (-1.37%)
As of 07/11/2025 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cyclerion Therapeutics Stock (NASDAQ:CYCN)

Key Stats

Today's Range
$3.55
$3.74
50-Day Range
$2.75
$3.64
52-Week Range
$1.27
$9.47
Volume
54,178 shs
Average Volume
1.28 million shs
Market Capitalization
$11.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cyclerion Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

CYCN MarketRank™: 

Cyclerion Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 700th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Cyclerion Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cyclerion Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cyclerion Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cyclerion Therapeutics has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cyclerion Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.49% of the float of Cyclerion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclerion Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclerion Therapeutics has recently decreased by 10.22%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cyclerion Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cyclerion Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.49% of the float of Cyclerion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclerion Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclerion Therapeutics has recently decreased by 10.22%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cyclerion Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cyclerion Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    34.30% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cyclerion Therapeutics' insider trading history.
Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYCN Stock News Headlines

Cyclerion Therapeutics files $25M mixed securities shelf
3 US Penny Stocks With Market Caps Over $10M To Consider
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Cyclerion Therapeutics announces update on next stage of growth
See More Headlines

CYCN Stock Analysis - Frequently Asked Questions

Cyclerion Therapeutics' stock was trading at $3.22 at the beginning of 2025. Since then, CYCN shares have increased by 13.0% and is now trading at $3.64.

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) posted its quarterly earnings results on Tuesday, March, 4th. The company reported $0.22 earnings per share for the quarter. The business had revenue of $1.81 million for the quarter.

Shares of Cyclerion Therapeutics reverse split on Tuesday, May 16th 2023.The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), GE Aerospace (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
3/04/2025
Today
7/13/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYCN
CIK
1755237
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.06 million
Net Margins
N/A
Pretax Margin
-141.47%
Return on Equity
-34.02%
Return on Assets
-30.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.21
Quick Ratio
4.21

Sales & Book Value

Annual Sales
$2.08 million
Price / Sales
5.61
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.27 per share
Price / Book
1.11

Miscellaneous

Outstanding Shares
3,210,000
Free Float
2,109,000
Market Cap
$11.68 million
Optionable
No Data
Beta
1.55
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:CYCN) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners